Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intratumoral CNSI-Fe injection combined with radiotherapy in solid tumors
CTR20260473Phase 2Active
- Sponsor
- Sichuan Yingrui Pharmaceutical Technology
- Start
- Jul 2026
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of CNSI-Fe in Nonhematologic neoplasms (2 cohorts), sponsored by Sichuan Yingrui Pharmaceutical Technology. Primary endpoint: Objective response rate. Started Jul 2026; status: active.
02
Drugs
CNSI-Fe
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260473.